Somerset ICB Medicine Management Score Card 2025/2026 Cardiovascular Indicator Supporting Tool May 2025



1

Background

CVDPREVENT is a national primary care audit that will automatically extract routinely held GP data, via GPES. It will provide a foundation for professionally led quality improvement in individual GP practices across Primary Care Networks (PCNs). The data helps highlight gaps, identify inequalities and monitor improvement and impact on inequalities, as well as enabling opportunities for improvement in diagnosis and management of the high-risk conditions for CVD.

Time for Action

Across NHS Somerset Integrated Care Board at the end of September 2024:

- 13,130 people with hypertension did not have a recent blood pressure reading
- **35,705 people** with hypertension were not treated to the appropriate blood pressure threshold
- 15,385 people at a high risk of CVD did not have a current prescription for lipid lowering therapy

Using the UCLPartners *Size of the Prize* resources, it is estimated that addressing the unmet treatment gap by initiating lipid-lowering therapy (LLT) in an additional **4,719 adults** with GP-recorded cardiovascular disease (CVD) who are currently not receiving LLT within **NHS Somerset Integrated Care Board** could prevent approximately **283 CVD events** and save **34 lives** ,potentially resulting in **cost avoidance of up to £3,024,704 for the local healthcare system** over the next three years.

To support increased in national focus on CVD prevention and the revised QOF indicators. The Somerset Medicines Program Board agreed a new scorecard indicator for the 2025/26 prescribing and quality improvement incentive scheme as follows:

CVDPrevent Indicators	Score Card Target for FY 25/26
Patients with GP recorded chronic kidney disease (G3a to G5), who are currently treated with lipid lowering therapy - CVDP010CHOL	>60%
Patients with no GP recorded CVD and a GP recorded QRISK score of 20% or more, who are currently treated with lipid lowering therapy - CVDP003CHOL	>65%
Patients with GP recorded CVD (narrow definition), who are currently treated with lipid lowering therapy - CVDP009CHOL	>85%

This will reward practices for achieving **2 out of 3** indicators (CVDP010CHOL/CVDP003CHOL/CVDP009CHOL) by latest published CVDPrevent data available in May 2026.

Little Something You Might Like to Know

- CVDPREVENT is a national primary care audit designed to support the prevention of cardiovascular disease through data-driven insights. The dataset is publicly available and can be accessed via the following link: <u>Regional & ICS Insights | CVDPREVENT</u>
- Comparison with QOF Indicators: Some of the CVDPREVENT GP-recorded prevalence and clinical treatment
 indicators are similar to those reported through the Quality and Outcomes Framework (QOF). However, the two
 systems are not identical, which leads to variations in reported figures. One key difference is that CVDPREVENT
 does not capture all clinical codes that GPs may use to indicate that a patient is either unsuitable for treatment
 or has opted out based on personal preference.

For further information on the methodology used by CVDPREVENT, please refer to: <u>CVDPREVENT Methodology</u> For details on business rules, see: <u>Cardiovascular Disease Prevention Audit (CVDPREVENT) – NHS England Digital</u>

Somerset ICB Medicine Management Score Card 2025/2026 Cardiovascular Indicator Supporting Tool May 2025



Supporting Resources

Eclipse VISTA Pathway – Lipids Optimisation Module & Chronic Kidney Disease Management Module

To access relevant information and support: Visit <u>https://secure.nhspathways.org</u> when using HSCN/N3. Log in with your existing Eclipse username and password. If you do not have login credentials, please contact the support team at support@prescribingservices.org

To access your practice's module, navigate to **"VISTA Pathways"**, then select the relevant modules—such as **Lipid Optimisation** and/or **CKD Management**—and click **"View"** to open them.

Advice & Guidance	kogast in as Marco Young (NHS 5	ismenen CCO] Logeen User i	onais Change Password SMR Quick : Potent Code											
Please Select Pathway of CF		QIC bets Eclipse QIC	SMRLåve	CONTROL PLUS 5 Corre20PLU55	8	Li <mark>pid Optimisa</mark> tion	603,650 99.8%	488 / 359 1,522 / 865	0.0% 0/0	0.00 / pt 0 / £0	0.00 /pt 0/£0	0.00 / pt 0 / £0	£0.00 / pt £0	View
Other					1	Maternity Care Surveillance - Currently pregnant and smoke	897 0.1%	1/1 0/0	0.0% 0/0	0.00 /pt 0/£0	0.00 /pt 0/£0	0.00 /pt 0/£0	£0.00 / pt £0	View
Other							890	1/1	0.0%	0.00	0.00	0.00	£0.00/	

Under "**Priority Patients**", you'll find a set of resources available—consider focusing on the **highlighted rows**, which may be particularly useful for optimising scorecard performance.

				Lipid Optimisation							
				Filters: None			Core20Pi	-LUS			
				Priority Groups	Total Patients (Lipid Optimisation)	Total Putients in othert	%. Patients in c				
				Cholesterol + 7.5mmol/L and no test in last 12 months	619923	1601	0.25%	V			
				Cholesterol + 7.5mmol/L and current smoker	619923	579	0.09%	V			
				Cholesterol + 7.5mmol/L and 8P +140/90	619923	1048	0.17%	V			
				Cholesterol > 7.5mmol/L and on statin	619923	605	0.11%	٧			
Pathway: Lipid Optimisation 4	way: Lipid Optimisation 4 NHS Somerset CCG 4 All Practices 4		14	Cholesterol > 7.5mmol/L and not on statin	619923	3158	0.51%	۷			
				Cholesterol > 7.5mmol/L and ischaemic heart disease	619923	145	0.02%	V			
				Cholesterol > 7.5mmol/L and peripheral vascular disease	619923	45	0.01%	V			
603650	A	0.00 Administrations per partient	0.00	Cholesterol > 7.5mmol/L and history of Droke / TiA	619923	70	0.01%	۷			
Patient Count	488 / 1522 Alerts	Admissions per padent	Admissions per patient	Choixesterol > 7.5mmol/L and diabetes	619923	346	0.06%	۷			
				Cholesterol + Immol/L aged +=30 and not referred for FH screening	619923	309	0.05%	۷			
 Comparison Chart 	s [Apr 25] Alert Suite Requ	off		Choixestarol > 9mmol/L at any time and not referred for FH screening	619923	2614	0.42%	V			
• comparison charc	s [Apr 25] Alert Suite Redu	est		Orcivesterol > 7 Striftol/L and estimated ORSR3 Score > 20% not on a state	619923	974	0.16%	V			
				Patient on Ezetimibe and Statis with HOL > 2.5	619923	13	0%	۷			
		_		On Statin and Ezetimibe with Non+HOL Cholesterol + 2.5	619923	1209	0.2%	۷			
A	I (I)			On Ezetimibe, not on a Statil, Non-HOL Cholesterol > 2.5	619923 Loa	iding		V			
				Not on a Statin, Non-HDL, Cholesterol + 2.5	619923	160172	29.06%	V			
Satoly Alerts	Patients Priority Patients	Working Well		On a Statin, not on Ezetimibe, Non-HOL Cholesterol + 2.5	619923	43398	7%	V			
				Patients with CVD, not on any fold-lowering therapy with non-HOL +2.5	619923	7972	1.29%	V			

UCL Partners Tool – Cholesterol (EMIS Searches)

The tools have been developed by UCL Partners Health Innovation clinical team, a set of their framework and risk stratification tool are available to consult here: <u>Search and risk stratification tools - UCLPartners</u>

It's worth noting that the UCL Cholesterol EMIS searches may cover a broader cohort of priority patients than those captured under the KPI9 scorecard.

Ardens EMIS LTC Population Report (EMIS Searches)

The Ardens Risk Stratification searches have been designed to help practices focus on chronic disease reviews on higher risk patients and to pro-actively priorities patients. Resources are available as follow as illustrated on Ardens website: 1.12 Chronic Disease Risk Stratification Searches : Ardens EMIS Web

To locate the searches navigate to the Population Reporting module > Ardens Searches > 1.12 LTC Reviews - Risk Strat > Chronic Disease Risk Stratification -	CVD Prevention This search folder is broken down by primary and secondary prevention.
UCLP criteria folder.	For primary prevention (no pre-existing CVD):
1.12 LTC Reviews - Risk Strat (Ardens v1.9) Chronic Disease Risk Stratification-UCLP criteria Eastma Eastma The Atrial Fibrillation	 Priority 1 - patients with a QRISK score more than 20% who have CKD or Diabetes, no CVD and not on a statin. Priority 2 - patients with a QRISK score 15-19% and not on statin. Priority 3 - patients with a QRISK score 10-14% and not on statin. Priority 4 - patients on statin for primary prevention but not on high intensity.
COPD	For secondary prevention (pre-existing CVD):
 ▷ CVD Prevention 	 Priority 1 - patients not on statin therapy. Priority 2 - patients on suboptimal statin dose. Priority 3 - patients with Non-HDL more than 2.5 despite max tolerated statin therapy.
	therapy.

Disclaimer: Supporting tool and search results are not indicative of final clinical decisions. Clinical prescribing and optimization should always be based on an individual patient's clinical background, including their medical history and comorbidities. Healthcare professionals should always consult British National Formulary and Summary of Product Characteristics for prescribing guidance, cautions, contraindications, and safety considerations.

Somerset ICB Medicine Management Score Card 2025/2026 Cardiovascular Indicator Supporting Tool May 2025



Eclipse Live Solution – Local Searches

To access Somerset's local eclipse searches, visit <u>Eclipse Login Page</u> when using HSCN/N3. Log in with your existing Eclipse username and password. If you do not have login credentials, please contact the support team at support@prescribingservices.org



Click **"Eclipse Live,"** then scroll to bottom to open "Other Alerts- info", where you will find a set of local CVD searches designed to support your daily prescribing practice.

	Eclipse Live Main Menu + HEALTH CENTRE						
Practice Portal	Last import date: 28/09/2014	Other Alerts - Red [72 Alert(s)] Click to View					
		Other Alerts - Amber [129 Alert(s)] Click to View					
	Run Adhoc Search 🛛 🎣 Eclipse Live Admin	Other Alerts - Info [151 Alert(s)] Click to View					
Prescribing Eclipse Live	Eclipse Live Messages Relating to Patients	End Totropium (any device) and ICS/LABA: Patients 10 Inv 13.20					
	- Unread Messages (0 Abertic)(No Messages	Clabetes: Namber of patient with Sulfonylureas prescribed via Patients Trepeat in last 90 days. San 06/04 14.29					
- A.	+ Read Messager [] Alexia] Oils with	Comminator: T2D Age 18+ and QBISK3 score =>200: 300 View Patients Sen 05/04 14/27					
Performance Construction	Your Alerts - (You have be served dirits (Intel 72)) - Ook have to size all B Doot RADA	20 Denominator: T1D Age 18+ : Patients San 06/04 53 View Patients 14:27					
	- RADAR - Red Alerts [2 Alerty]; Causs Vee	Child above 2 prescribed milk powder: Patients San 06/04 14/27					
	0 = On ItSARDS with renal impairment ingle+30: 1 Voir Relation 1939	Sim 06/04 Denominator for AE: T2D with CVD coded: 183 View Pasients 14.26					
Eclipse Live Messages Relating to Patients	0 = Meannaire Cat. Patients 1 Sectore State Patients 1 Sectore State Sta	Weight Loss 01: Tirzepadde Issued in last 90days : Patients Sam 06/04 14/26					
Unread Messages [0 Alert(s)]	 RADAR - Anther Alerts [] - A Alerts[] Cisk to Ves 	Weight Loss 02: Tirzepatide issued in last 90days with T2D Patients Coded San 06/04 14/25					
No Messages	A = togethair Throndocissena on Antgranier. 3	Sant DB/D4 S					
Read Messages [2 Alert(s)] Click to View	Lance High Chalesteric Father's Latent Chalesterial Brend I's and Poor A State	14.25					

A set of local CVD Eclipse live searches* has been created to support Practices and PCNs enabling opportunities

for improvement in management of the high-risk conditions for CVD.

*Note If no patients meet the alert criteria, the alert description will not be displayed.

Version 1 – 2025:

Cholesterol Primary Prevention: Age 25-84Ys, No hx of CVD coded, QRISK score =>20%, not on LLT or statin in last 90 days. Diabetes Medicine Value 06: Type 2 diabetes (Age 25-84Ys, exclude already with hx of CVD) with QRISK > = 20%, not on statin or LLT in last 90 days. Diabetes Medicine Value 07: Statin Primary prevention for people age =>40Ys with type 1 diabetes, not on statin or LLT in last 90 days. Cholesterol Primary Prevention: Chronic kidney disease, no hx of CVD, latest eGFR < 60ml/min, not on statin or LLT in last 90 days. Cholesterol Secondary Prevention: History of CVD coded, no LLT or statin in last 12 months.

As of the date this document was written, our understanding is that the above support tools do not capture all clinical codes that GPs may use to indicate that a patient is either unsuitable for treatment or has opted out/declined based on personal preference.

National Lipids Management Guidance:

- NHSE Summary of national guidance for lipid management : <u>NHS Accelerated Access Collaborative »</u> <u>Summary of national guidance for lipid management</u>
- NHSE Statin Intolerance Pathway: NHS Accelerated Access Collaborative » Statin intolerance pathway

Other Useful Resources:

The following resources can help with explaining the benefits and risks of statins to patients:

- NICE <u>Are statins the best choice for me?</u>
- NICE <u>Tools and resources | Cardiovascular disease: risk assessment and reduction, including lipid</u> <u>modification | Guidance | NICE</u>
- PHE Health Matters: What you need to know about statins UK Health Security Agency
- British Heart Foundation <u>Statins information sheet</u>